Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Todd Neale

August 30, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Daily News

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

March 09, 2013

Advertisement

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

What’s Going to Be Hot at ESC 2022?

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content